Hims & Hers HUGE Acquisition News!

Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.Hims & Hers (HIMS +0.00%) announced the $1.15 billion acquisition of Australian telehealth company Eucalyptus, which will add $450 million in annualized revenue to the company. This isn't a company shying away from recent legal action, it's scaling internationally as fast as possible. In this video, I go through the upside from this acquisition as well as the downside of using most of the cash on the balance sheet, which was once a backstop for investors. *Stock prices used were end-of-day prices of Feb. 19, 2026. The video was published on Feb. 19, 2026. Read NextFeb 9, 2026 •By Emma NewberyStock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk LawsuitFeb 9, 2026 •By Bram BerkowitzHims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?Feb 9, 2026 •By Rich SmithWhy Hims & Hers Stock Just Got DestroyedFeb 5, 2026 •By Travis HoiumHims & Hers Takes On Novo Nordisk: What We Know Right NowFeb 5, 2026 •By Rich SmithWhy Eli Lilly Stock Just DroppedFeb 4, 2026 •By Travis HoiumHUGE News: Hims & Hers Adds Cancer Testing to Labs OfferingAbout the AuthorTravis Hoium is a contributing Motley Fool stock market analyst covering solar energy, technology, and growth stocks.

Before The Motley Fool, Travis was a mechanical engineer at 3M and founded a virtual reality company. He holds a bachelor’s degree in mechanical engineering and a master’s degree in business administration from the University of Minnesota.TMFFlushDrawX@travishoiumStocks MentionedHims & Hers HealthNYSE: HIMS$15.84 (+0.00%) $+0.00Novo NordiskNYSE: NVO$48.46 (1.56%) $0.77*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.